Trinity Biotech PLC - Form 6-K Filing

Trinity Biotech PLC filed a Form 6-K report for the month of December 2025, incorporating by reference Exhibits 99.1 and 99.2. These exhibits contain the company's Condensed Interim Unaudited Consolidated Financial Statements as of June 30, 2025, and for the six-month periods ended June 30, 2025, and June 30, 2024. Additionally, the report includes Management's Discussion and Analysis of Results of Operations, Liquidity, and Cash Flows for the same periods. The financial statements detail the company's assets, liabilities, equity, and comprehensive income, highlighting a loss for the six-month period ended June 30, 2025, of $14,764,000, compared to a loss of $10,074,000 for the corresponding period in 2024. Key financial activities include changes in revenues, cost of sales, operating expenses, and financing costs. The company operates in the diagnostics market, focusing on diabetes management and human diagnostics, with segments in the Americas and Rest of World.